Neumora Therapeutics, Inc. (NMRA)
| Market Cap | 1.68B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -131.66M |
| Shares Out | 151.95M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 771,019 |
| Open | 11.01 |
| Previous Close | 11.01 |
| Day's Range | 10.47 - 11.62 |
| 52-Week Range | 9.90 - 17.74 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 15, 2023 |
About NMRA
Neumora Therapeutics is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. We have rapidly scaled our therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. We expect to continue to progress the development of our pipeline wit... [Read more]
Financial Performance
Financial StatementsNews
Neumora Therapeutics Announces Pricing of Initial Public Offering
WATERTOWN, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pr...
SoftBank-backed Neumora Therapeutics files paperwork for U.S. IPO
Neumora Therapeutics, a biopharmaceutical firm backed by biotech Amgen and Japans SoftBank , on Friday filed for an initial public offering of its shares in New York.
Neumora Therapeutics IPO Registration Document (S-1)
Neumora Therapeutics has filed to go public with an IPO on the NASDAQ.